JOC The Journal of Organic Chemistry

pubs.acs.org/joc Article

Synthesis of Lactams via Ir-Catalyzed C−H Amidation Involving Ir-Nitrene Intermediates

Jitian Liu,* Wenjing Ye, Shuojin Wang, Junrong Zheng, Weiping Tang, and Xiaoxun Li*

Cite This: J. Org. Chem. 2020, 85, 4430−4440 Read Online



ABSTRACT: *x*-membered lactams were synthesized via either an amidation of sp^3 C−H bonds or an electrophilic substitution of arenes via Ir-nitrene intermediates. With the employment of a readily available iridium catalyst in dichloromethane or hexafluoro-2-propanol, a wide range of lactams were synthesized in good to excellent yields with high selectivity.

■ INTRODUCTION

The five- and six-membered lactam rings are found not only in various natural products with diverse biological activities[1] but also in a number of synthetic bioactive compounds and clinical drugs.[2] Previously, numerous methods were developed for the construction of a N-substituted lactam motif because of its high utility.[3] One of the most versatile strategies is direct transformation of aliphatic C−H bonds into valuable C−N bonds.[4] Since the initial report of intramolecular nitrene C−H insertions mediated by transition−metal complexes a few decades ago,[5] numerous methods have been reported for the C−H amidation reaction.[6] However, most of these reactions afforded carbamates or sulfamates. Direct formation of cyclic amides or lactams through C−H amidation remained elusive until recently[7] because free nitrenes derived from amides can easily undergo Curtius-type rearrangement to form isocyanates (Scheme 1a). Using dioxazolone[8] as the nitrene precursor and a series of carefully designed Ir complexes as the catalysts, the formation of lactams via Ir-catalyzed C−H amidation reaction was realized by Chang and Baik in 2018 as one of the major breakthroughs in the area of C−H functionalization.[7a] Moreover, several groups reported the formation of chiral *γ*-lactams via enantioselective intramolecular C−H amidation in 2019 (Scheme 1a).[9] The formation of *δ*-lactams using the same strategy was also achieved by Chang with different iridium catalysts (Scheme 1b).[7a,10]

In the present study, we further explore the employment of our recently developed readily available Ir catalysts[11] for the synthesis of various lactams via either C−H insertion to sp^3 C−H bonds or electrophilic substitution of electron-rich arenes (Scheme 1c).

Scheme 1. Dioxazolones as the Nitrene Precursors



■ RESULTS AND DISCUSSION

We first examined the reactivity of different catalysts in the C−H amidation reaction. We selected 3-[3-(thiophen-2-yl)-propyl]-1,4,2-dioxazol-5-one (**1a**) as the model substrate. When 0.5 mol % of **cat-3** was used as the catalyst with equal amount of sodium tetrakis(3,5-bis(trifluoromethyl)phenyl)-borate (NaBAr$^F_4$) in dichloromethane (DCM), only trace amount of the product was detected (Table 1, entry 1). After

Received: January 20, 2020
Published: February 27, 2020

   https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

Table 1. Optimization of Ir-Catalyzed C−H Amidation[a]



entry	catalyst (mol %)	$NaBAr^F_4$ (mol %)	solvent	yield[b] (%)
1	**cat-3** (0.5)	0.5	DCM	8
2	**cat-3** (1)	1	DCM	43
3[c]	**cat-3** (2)	2	DCM	67
4[c]	**cat-3** (2)	4	DCM	89
5[c]	**cat-3** (5)	10	DCM	88
6[c]	**cat-1** (2)	4	DCM	59
7[c]	**cat-2** (2)	4	DCM	61
8[c]	**cat-4** (2)	4	DCM	31
9[c]	**cat-5** (2)	4	DCM	38
10[c]	**cat-6** (2)	4	DCM	46
11[c]	**cat-7** (2)	4	DCM	39
12[c]	**cat-8** (2)	4	DCM	52
13	**cat-3** (2)	4	MeOH	11
14	**cat-3** (2)	4	dioxane	10
15	**cat-3** (2)	4	THF	12
16	**cat-3** (2)	4	MeCN	24
17	**cat-3** (2)	4	EtOAc	34
18[d]	**cat-3** (2)	4	DCE	68

[a]The reactions were performed on a 0.2 mmol scale for 12 h. [b]The yield was determined and calculated by ^{1}H NMR with 1,3,5-trimethoxybenzene as the internal standard. [c]The reaction time was 20 h. [d]DCE was the abbreviation of 1,2-dichloroethane.

increasing the catalyst loading, moderate to good yields were obtained (Table 1, entries 2 and 3). When the ratio of the $NaBAr^F_4$ additive to the Ir catalyst was increased to 2:1, the yield was improved from 67 to 89% (Table 1, entry 4).

We then examined the effect of different R-substituents on the pyridine ring of our catalysts. 4-Dialkylamino-substituted catalysts **cat-1** and **cat-2** delivered 59 and 61% yields, respectively (Table 1, entries 6 and 7). The 3-, 4-, and 5-methoxy-substituted catalysts **cat-4**, **cat-5**, and **cat-6** gave lower yields (31, 38, and 46%, respectively, as shown in entries 8−10). 4-Chloro-substituted **cat-7** gave 39% yield, while the more electron-withdrawing cyano-substituted **cat-8** delivered 52% yield (Table 1, entries 11 and 12). Of all the catalysts screened, **cat-3** exhibited the best activity for the C−H amidation reaction. The starting material for the ligand of this catalyst is also the least expensive compared to other ligands. Other solvents did not provide any improvement over DCM.

After the optimization of the reaction conditions, a wide range of substrates were examined for this C−H amidation (Table 2). Dioxazolones, used as substrates in this reaction, were easily prepared from commercially available carboxylic acids following literature procedures.[7a,12] Thiophene **2a** was obtained in 89% isolated yield. Benzylic substrates also gave good yields (**2b**, **2c**), while *para*-methyl-substituted benzylic product **2d** was prepared in only 51% yield. Allylic lactam (**2e**)

Table 2. Scope of Intramolecular C−H Amidation[a]



[a](A) Functionalization of aliphatic sp^3 C−H bonds. (B) Functionalization of aromatic sp^2 C−H bonds. Unless otherwise indicated, the reaction conditions were as follows: 2 mol % of **cat-3**, 4 mol % of $NaBAr^F_4$, and DCM at 40 °C for 12 h. [b]5 mol % catalyst was used. [c]10 mol % catalyst was used. [d]Hexafluoro-2-propanol (HFIP) was used as a solvent. [e]Run at 50 °C. [f]Run at 60 °C. [g]Reaction time was 4 h. [h]Reaction time was 24 h. [i]Reaction time was 36 h.

was also obtained in good yield. Cyclopentyl **2f**, which had nonactivated secondary C−H bonds, was also successfully synthesized. Insertion to tertiary C−H bonds yielded products **2g** and **2h**. When ortho-substituted benzamides were employed, 3-substituted isoindolinones (**2i**, **2j**, **2k**, **2l**) were prepared in good to excellent yields. Treatment of *N*-phthalimide-protected gabapentin derivative with our catalyst also gave the corresponding lactam **2m** in 92% yield.

As shown in Table 2B, five- and six-membered lactams bearing an aniline moiety could also be prepared using our catalyst **cat-3**. Meta-substituted phenylacetyl substrate gave a mixture of isomeric desired products (**2n**, **2n′**) in a total of 81% yield with 4:1 regioselectivity. 3,4-Dimethoxy-substituted dioxazolones generated lactams **2o** and **2p** in excellent yields, respectively. Dihydroquinolinone **2q** was also synthesized from the corresponding 3,4,5-trimethoxy-substituted substrate in 99% yield. It is worth mentioning that the *meta*-methoxy-substituted dihydroquinolinone **2r** was obtained as the major isomer with a regioselectivity of more than 20:1, presumably because the cyclization to the ortho-position is sterically too congested. When naphthylethyl dioxazolone was used as the substrate, tricyclic dihydroquinolinone product **2s** was obtained successfully.

When we examined the *para*-methoxy-substituted hydrocinnamyl substrates under the amidation conditions, unexpected rearrangement products were obtained. We then examined the scope of this rearrangement reaction, as shown in Table 3. *Para*-methoxy-substituted dioxazolone gave the corresponding product **2r** in 99% yield. When the substitute was replaced by a methyl group, **4b** was obtained in 87% yield.

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

Table 3. Scope of Benzo-Fused δ-Lactams via Skeletal Rearrangement[a]



[a]Unless otherwise indicated, the reaction conditions were as follows: 2 mol % of catalyst, 4 mol % of NaBAr$^F_4$, and DCM at 40 °C for 12 h. [b]Hexafluoro-2-propanol was used as a solvent. [c]Run at 50 °C. [d]Reaction time was 2 h.

Table 4. Scope of Dearomative Spirocyclization Reaction[a]



[a]Unless otherwise indicated, the reaction conditions were as follows: 2 mol % of catalyst, 4 mol % of NaBAr$^F_4$, and HFIP at 60 °C for 12 h. [b]DCM was used as a solvent. [c]Run at 40 °C.

However, the reaction with the Boc-protected amino substituent gave a relatively low yield (**4c**). The cyclization reaction occurred efficiently with high regioselectivity on the more electron-rich methoxy-substituted phenyl to give **4d** in 93% yield. The rearrangement product was also found for ortho-substituted substrates. Reaction of an *ortho*-methoxy-substituted phenylethyl dioxazolone proceeded in moderate yield (**4e**). However, when the substitute was replaced by a methyl group, the product **4f** was generated in a relatively low yield. Tricyclic product **4g** was also prepared in a moderate yield. In addition, five-membered ring cyclization reaction also proceeded smoothly to generate product **2n** in satisfactory yield.

To further investigate the mechanism of the skeletal rearrangement, a range of phenol-based dioxazolones were examined under the reaction conditions, as shown in Table 4.

To our delight, when *para*-hydroxyl-substituted dioxazolone was used as the substrate, the *aza*-spirodienone product **6a** was isolated in 99% yield. It appeared that the spirocyclization reaction occurred first, and it was followed by a C−C migration to form the rearrangement products. Chang's group reported similar reactions using their Ir catalysts.[10] Other phenol-based dioxazolones having additional substituents also proceeded well. Ortho- and meta-substituted hydroxy phenol substrates generated the corresponding products **6b** and **6c** in excellent yield, respectively. Derivatives bearing multiple substituents also underwent the dearomative spirocyclization reaction smoothly (**6d**, **6e**, **6f**). *N*-Phthalimide-protected tyrosine afforded lactam **6g** in 97% yield. It needs to be emphasized that *ortho*-hydroxyl-substituted dioxazolone under the same reaction condition generated spirolactam **7a** in moderate yield.

Furthermore, this reaction was scalable, as demonstrated in the gram-scale experiments. For example, 2 g of dioxazolone **1p** and 1.3 g of **5a** were facilely converted to the corresponding lactams **2p** and **6a** in excellent yields (91 and 87%, respectively) as shown in Scheme 2, enhancing the synthetic utility of this method.

Scheme 2. Gram-Scale Synthesis of Lactams



A plausible mechanism including two different pathways for the iridium-catalyzed C−H amidation is proposed in Scheme 3. In pathway **A**, an Ir-catalyzed insertion of Ir nitrene into the sp^3 C−H bond was proposed. Coordination of the Ir catalyst to dioxazolone in **1a** will induce the formation of Ir-nitrene **III**, releasing a molecule of carbon dioxide. Insertion of Ir nitrene to the C−H bond through **IV** would yield product **2a**. In pathway **B**, an electrophilic aromatic substitution mechanism was proposed for the amidation of the sp^2 C−H bond. When *para*- or *ortho*-hydroxyl-substituted phenol dioxazolones were used, cyclization of intermediate **V** and the removal of the proton on the phenolic oxygen can generate spirolactam **6a** directly. Otherwise, cyclization of intermediate **V** will afford the spirocyclic amido intermediate **VI**, which can then undergo 1,2-migration and rearomatization to yield the ring-expanded rearrangement product **2r**.

In summary, we have successfully synthesized a series of five- and six-membered lactams using an iridium complex developed previously via amidation of sp^3 or sp^2 C−H bonds. A wide range of five- and six-membered lactams were successfully prepared in good to excellent yields with the employment of

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

Scheme 3. Proposed Mechanism of C−H Amidation



up to 2 mol % iridium catalyst. Using dioxazolones as the nitrene precursor, five-membered lactams were synthesized via insertion of the Ir-nitrene intermediate to sp^3 C−H bonds. Electrophilic substitution occurred for substrates with an electron-rich aryl substituent on the γ- or δ-position of the dioxazolones. Further studies concerning the development of an enantioselective variant for the preparation of chiral γ-lactams are currently underway in the laboratory.

■ EXPERIMENTAL SECTION

General Information. All reactions in nonaqueous media were conducted under atmospheric conditions in glassware that had been oven dried prior to use unless noted otherwise. Oxygen- and moisture-sensitive reactions were carried out under the argon atmosphere. All commercially available reagents were used without further purification unless otherwise noted. Thin-layer chromatography was performed using precoated silica gel plates (QC3724, F254). Flash column chromatography was performed with silica gel (Sillicycle, 50−75 μm). ^{1}H and ^{13}C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 400 MHz or 500 MHz recorded in parts per million (ppm) (δ) downfield of TMS (δ = 0) in $CDCl_3$. Signal splitting patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), or multiplet (m), with coupling constants (J) in hertz.

General Procedure A for the Preparation of 3-Substituted-1,4,2-Dioxazol-5-ones.



To a solution of carboxylic acid (10 mmol) in dry tetrahydrofuran (THF, 20 mL) was added 1,1′-carbonyldiimidazole (CDI, 15 mmol, 1.5 equiv). The reaction mixture was stirred for 1 h before hydroxylamine hydrochloride (20 mmol, 2.0 equiv) was added. The resulting mixture was stirred overnight. The mixture was diluted with 5% aq $KHSO_4$ (20 mL) and extracted with ethyl acetate. The combined organic phase was washed with brine (20 mL) and dried over anhydrous Na_2SO_4. The extract was filtered and concentrated to give the residue that was used directly for the next step.

To a solution of unpurified hydroxamic acid (5 mmol) in dry DCM (20 mL) was added CDI (5.5 mmol, 1.1 equiv). The mixture was stirred for 5 min to 1 h until the reaction was complete. 2 N HCl solution (10 mL) was added and extracted with CH_2Cl_2. The combined organic phase was collected and dried over Na_2SO_4. The extract was filtered, concentrated, and purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate = 10:1) to give 3-substituted-1,4,2-dioxazol-5-ones.

General Procedure B for the Preparation of 3-Substituted-1,4,2-Dioxazol-5-ones.



To a solution of carboxylic acid (2.0 mmol) in DCM (20 mL) were added oxalyl chloride (4.0 mmol) and dimethylformamide (2 drops) at 0 °C. The mixture was allowed to stir at room temperature for 2.5−4 h, the reaction mixture was concentrated, and then the crude product was used directly for the next reaction.

Hydroxylamine hydrochloride (1.2 equiv) was added to a biphasic mixture of K_2CO_3 (2.0 equiv) in a 2:1 mixture of EtOAc (10 mL) and H_2O (5 mL). The resulting solution was cooled to 0 °C, followed by dropwise addition of the unpurified acid chloride dissolved in a minimum amount of EtOAc under air. The reaction was warmed to room temperature and stirred for an additional 12 h. The phases were separated, and the aqueous phase was extracted twice with EtOAc. The combined organic layer was collected and dried over Na_2SO_4. The extract was filtered and concentrated to give the residue that was used directly for the next step.

To a solution of unpurified hydroxamic acid (5 mmol) in dry DCM (20 mL) was added CDI (5.5 mmol, 1.1 equiv). The mixture was stirred for 5 min to 1 h until the reaction was complete. 2 N HCl solution (10 mL) was added and extracted with CH_2Cl_2. The combined organic phase was collected and dried over Na_2SO_4. The extract was filtered, concentrated, and purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate = 10:1) to give 3-substituted-1,4,2-dioxazol-5-ones.

General Procedure C for the Preparation of 3-Substituted-1,4,2-Dioxazol-5-ones.



To a solution of carboxylic acid (10 mmol) in diethylether (30 mL) were added ethylchloroformate (12 mmol, 1.2 equiv) and N-methylmorpholine (13 mmol, 1.3 equiv) at 0 °C, and the mixture was stirred for 10 min. The solid was filtered off, and

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

the filtrate was added to freshly prepared hydroxylamine (15 mmol, 1.5 equiv) in methanol. The reaction mixture was stirred at room temperature for 15 min. The solvent was evaporated, and the residue was purified by silica gel column chromatography to give hydroxamic acid.

To a solution of hydroxamic acid (5 mmol) in dry DCM (20 mL) was added CDI (5.5 mmol, 1.1 equiv). The mixture was stirred for 5 min to 1 h until the reaction was complete. 2 N HCl solution (10 mL) was added and extracted with CH_2Cl_2. The combined organic phase was collected and dried over Na_2SO_4. The extract was filtered, concentrated, and purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate = 10:1) to give 3-substituted-1,4,2-dioxazol-5-ones.

General Procedure D for the Preparation of 3-Substituted-1,4,2-Dioxazol-5-ones.



Carboxylic acid (20 mmol) was dissolved in methanol (40 mL), and sulfuric acid (conc., 0.4 mL) was added. The reaction mixture was heated to reflux for 6 h until full conversion. Solid $KHCO_3$ was added to neutralize the solution. After filtration, the slightly yellow solution was evaporated to dryness. The residue was dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution and saturated sodium chloride solution. The organic layer was dried and concentrated to give methyl ester.

The methyl ester compounds (10 mmol) and hydroxylamine hydrochloride (30 mmol, 3 equiv) were suspended in methanol (50 mL), followed by the addition of potassium hydroxide (60 mmol, 6 equiv). The mixture was heated at reflux for 12 h. After the reaction, the mixture was acidified with 1 N HCl to pH 4 and then concentrated under reduced pressure to remove methanol. The resultant was dissolved in water and extracted with ethyl acetate. The combined organic phase was dried and concentrated, and the crude mixture was purified by silica gel column chromatography to obtain hydroxamic acid.

To a solution of unpurified hydroxamic acid (5 mmol) in dry DCM (20 mL) was added CDI (5.5 mmol, 1.1 equiv). The mixture was stirred for 5 min to 1 h until the reaction was complete. 2 N HCl solution (10 mL) was added and extracted with CH_2Cl_2. The combined organic phase was collected and dried over Na_2SO_4. The extract was filtered, concentrated, and purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate = 10:1) to give 3-substituted-1,4,2-dioxazol-5-ones.

General Procedure E for the Preparation of 3-Substituted-1,4,2-Dioxazol-5-ones.



To a solution of aldehyde (10 mmol) in 50 mL of DCM was added ethyl (triphenylphosphoranylidene) acetate (15 mmol) at 0 °C in several portions, and the mixture was stirred at room temperature overnight. After the reaction, the solvent was removed, and the residue was purified on a flash silica gel column to give the product.

To a solution of alkene (4 mmol) in 20 mL of EtOH was added 5 wt % Pd/C (10 mol %). Then, the flask was vacuumed and refilled with hydrogen. The process was repeated three times, and the mixture was stirred at room temperature overnight. After the reaction, the reaction mixture was filtered over a pad of Celite, and the filtrate was concentrated to give the crude product that was used directly for the next step.

To a solution of ethyl ester (2 mmol) in 20 mL of methanol was added sodium hydroxide (5 mmol) in one portion. Then, the mixture was stirred at room temperature overnight. After the reaction, methanol was removed using a rotary evaporator, and water was added. Then, 1 N HCl was added to pH 1−2 and extracted with ethyl acetate. The combined organic phase was collected and concentrated to give the crude product that was used for the next step without further purification.

To a solution of carboxylic acid (2 mmol) in dry THF (15 mL) was added CDI (3 mmol, 1.5 equiv). The reaction mixture was stirred for 1 h before hydroxylamine hydrochloride (20 mmol, 2 equiv) was added. The resulting mixture was stirred overnight. The mixture was diluted with 5% aq $KHSO_4$ (20 mL) and extracted with ethyl acetate. The combined organic phase was washed with brine (20 mL) and dried over Na_2SO_4. The extract was filtered and concentrated to give the residue that was used directly for the next step.

To a solution of unpurified hydroxamic acid (1.5 mmol) in dry DCM (20 mL) was added CDI (1.5 mmol, 1.0 equiv). The mixture was stirred for 5 min to 1 h until the reaction was complete. 1 N HCl solution (10 mL) was added and extracted with CH_2Cl_2. The combined organic phase was collected and dried over Na_2SO_4. The extract was filtered, concentrated, and purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate = 10:1) to give 3-substituted-1,4,2-dioxazol-5-ones.

*3-(3-(Thiophen-2-yl)propyl)-1,4,2-dioxazol-5-one (**1a**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (900 mg, 76%);^{1}H NMR (400 MHz, $CDCl_3$): δ 2.10 (quintet, J = 7.6 Hz, 2H), 2.66 (t, J = 7.6 Hz, 2H), 2.97 (t, J = 7.6 Hz, 2H), 6.82 (dd, J = 0.8, 3.4 Hz, 1H), 6.94 (dd, J = 3.4, 5.2 Hz, 1H), 7.16 (dd, J = 1.2, 5.2 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 23.8, 26.2, 28.6, 123.9, 125.2, 127.0, 142.3, 154.1, 166.3.

*3-(3-Phenylpropyl)-1,4,2-dioxazol-5-one (**1b**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (360 mg, 98%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.03 (quintet, J = 7.4 Hz, 2H), 2.58 (t, J = 7.4 Hz, 2H), 2.71 (t, J = 7.4 Hz, 2H), 7.16 (d, J = 7.2 Hz, 2H), 7.21 (d, J = 7.2 Hz, 1H), 7.29 (t, J = 7.2 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 24.0, 25.9, 34.6, 126.5, 128.5, 128.7,140.0, 154.2, 166.6.

*3-(3-(4-Methoxyphenyl)propyl)-1,4,2-dioxazol-5-one (**1c**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (200 mg, 89%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.02 (quintet, J = 7.4 Hz, 2H), 2.60 (t, J = 7.4 Hz, 2H), 2.68 (t, J = 7.4 Hz, 2H), 3.79 (s, 3H), 6.85 (d, J = 8.8 Hz, 2H), 7.09 (d, J = 8.8 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 24.0, 26.1, 33.7, 55.3, 114.1, 129.4, 131.8, 154.1, 158.3, 166.5.

*3-(3-(p-Tolyl)propyl)-1,4,2-dioxazol-5-one (**1d**).*[9b] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (180 mg, 64%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.04 (quant, J = 7.6 Hz, 2H), 2.33 (s, 3H), 2.60 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.6 Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 21.0, 24.0, 26.0, 34.1, 128.3, 129.3, 136.1, 136.7, 154.1, 166.5.

*3-(Pent-4-en-1-yl)-1,4,2-dioxazol-5-one (**1e**).*[9c] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (280 mg, 72%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.84 (quintet, J = 7.2 Hz, 2H), 2.19 (q, J = 7.2 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 5.02−5.12 (m, 2H), 5.71−5.82 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 23.5, 24.0, 32.5, 116.6, 136.4, 154.2, 166.6.

*3-(Cyclopentylmethyl)-1,4,2-dioxazol-5-one (**1f**).*[9c] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

= 10:1; colorless oil (379 mg, 92%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.22−1.29 (m, 2H), 1.55−1.73 (m, 4H), 1.85−1.93 (m, 2H), 2.24 (quintet, *J* = 7.6 Hz, 1H), 2.62 (d, *J* = 7.6 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 24.9, 30.4, 32.3, 36.0, 154.3, 166.5.

*3-(2-Cyclohexylethyl)-1,4,2-dioxazolidin-5-one (**1g**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (500 mg, 46%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 0.89−0.98 (m, 2H), 1.13−1.34 (m, 4H), 1.60 (q, *J* = 8.4 Hz, 2H), 1.66−1.75 (m, 5H), 2.64 (t, *J* = 7.8 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 22.3, 26.0, 26.3, 31.7, 32.7, 36.8, 154.2, 167.1.

*3-Isopentyl-1,4,2-dioxazol-5-one (**1h**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (350 mg, 59%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 0.88 (d, *J* = 6.3 Hz, 6H), 1.51−1.63 (m, 3H), 2.56 (t, *J* = 7.6 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 20.9, 21.8, 26.4, 32.1, 153.2, 166.0.

*3-(2-Benzylphenyl)-1,4,2-dioxazol-5-one (**1i**).*[9d] Prepared according to general procedure B; eluent: petroleum ether/ethyl acetate = 10:1; white solid (190 mg, 62%); mp 77−80 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 4.31 (s, 2H), 7.11 (d, *J* = 7.0 Hz, 2H), 7.21 (dt, *J* = 2.0, 7.2 Hz, 1H), 7.27 (t, *J* = 7.6 Hz, 3H), 7.37 (td, *J* = 1.0, 7.8 Hz, 1H), 7.52 (td, *J* = 1.2, 7.6 Hz, 1H), 7.74 (dd, *J* = 1.2, 7.8 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 39.9, 119.3, 126.6, 127.1, 128.7, 129.1, 129.4, 132.0, 133.4, 138.9, 141.8, 153.6, 163.8.

*3-(2-Isopropylphenyl)-1,4,2-dioxazol-5-one (**1j**).*[7a] Prepared according to general procedure B; eluent: petroleum ether/ethyl acetate = 10:1; white solid (55 mg, 73%); mp 52−55 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.29 (d, *J* = 6.8 Hz, 6H), 3.60 (qui, *J* = 6.8 Hz, 1H), 7.35 (td, *J* = 1.4, 7.8 Hz, 1H), 7.54 (dd, *J* = 0.9, 7.8 Hz, 1H), 7.60 (td, *J* = 1.2, 8.0 Hz, 1H), 7.68 (dd, *J* = 1.2, 8.0 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 23.6, 30.3, 118.3, 126.4, 127.0, 129.3, 133.5, 150.0, 153.8, 164.1.

*3-(2-Ethylphenyl)-1,4,2-dioxazol-5-one (**1k**).*[7a] Prepared according to general procedure B; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (160 mg, 52%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.27 (t, *J* = 7.6 Hz, 3H), 2.96 (q, *J* = 7.6 Hz, 2H), 7.36 (t, *J* = 7.8 Hz, 1H), 7.41 (d, *J* = 7.8 Hz, 1H), 7.56 (td, *J* = 1.2, 7.6 Hz, 1H), 7.74 (dd, *J* = 1.0, 7.8 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 14.9, 27.7, 118.6, 126.5, 129.1, 130.4, 133.4, 145.3, 153.8, 163.9.

*3-(2-Phenethylphenyl)-1,4,2-dioxazol-5-one (**1l**).* Prepared according to general procedure B; eluent: petroleum ether/ethyl acetate = 10:1; white solid (190 mg, 29%); mp 88−91 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.87 (t, *J* = 7.6 Hz, 2H), 3.22 (t, *J* = 7.6 Hz, 2H), 7.16 (dd, *J* = 7.0, 17.8 Hz, 3H), 7.25 (t, *J* = 7.6 Hz, 2H), 7.33 (dd, *J* = 7.6, 17.8 Hz, 2H), 7.50 (td, *J* = 0.8, 7.6 Hz, 1H), 7.69 (d, *J* = 7.6 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 36.9, 37.3, 119.0, 126.3, 126.9, 128.5, 128.7, 129.2, 131.2, 133.3, 140.8, 142.7, 153.7, 163.8; HRMS (ESI) *m*/*z*: calcd for $C_{16}H_{13}NO_3Na$ [M + Na], 290.0793; found, 290.0783.

*2-((1-((5-Oxo-1,4,2-dioxazol-3-yl)methyl)cyclohexyl)methyl)-isoindoline-1,3-dione (**1m**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (260 mg, 24%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.38−1.58 (m, 8H), 1.66−1.78 (m, 2H), 2.75 (s, 2H), 3.78 (s, 2H), 7.76 (d, *J* = 2.8 Hz, 2H), 7.84 (d, *J* = 2.8 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 21.3, 25.3, 31.9, 33.4, 38.6, 45.2, 123.4, 131.8, 134.3, 154.0, 165.2, 169.1.

*3-(3-Methoxybenzyl)-1,4,2-dioxazol-5-one (**1n**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (350 mg, 52%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 3.80 (s, 3H), 3.87 (s, 2H), 6.81 (t, *J* = 2.0 Hz, 1H), 6.84−6.89 (m, 2H), 7.28 (t, *J* = 7.8 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 31.2, 55.3, 113.8, 114.8, 121.2, 130.3, 131.8, 154.0, 160.2, 165.3.

*3-(3,4-Dimethoxybenzyl)-1,4,2-dioxazol-5-one (**1o**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; white solid (61 mg, 76%); mp 95−97 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 3.87 (s, 2H), 3.88 (s, 3H), 3.89 (s, 3H), 6.78 (s, 1H), 6.85 (s, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 30.9, 55.9, 56.0, 111.6, 111.9, 121.4, 122.6, 149.2, 149.5, 154.0, 165.5.

*3-(3,4-Dimethoxyphenethyl)-1,4,2-dioxazol-5-one (**1p**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; white solid (530 mg, 59%); mp 60−62 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.92 (d, *J* = 6.4 Hz, 2H), 2.97 (d, *J* = 6.4 Hz, 2H), 3.87 (d, *J* = 2.8 Hz, 6H), 6.71−6.75 (m, 2H), 6.82 (d, *J* = 8.0 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 26.9, 30.1, 55.9, 56.0, 111.5, 111.6, 120.2, 130.5, 148.2, 149.2, 154.0, 165.9.

*3-(3,4,5-Trimethoxyphenethyl)-1,4,2-dioxazol-5-one (**1q**).* Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; white solid (450 mg, 64%); mp 99−102 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.96 (q, *J* = 4.8 Hz, 4H), 3.83 (s, 3H), 3.85 (s, 6H), 6.41 (s, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 26.8, 30.9, 56.2, 60.9, 105.2, 133.7, 137.1, 153.5, 154.0, 165.8; HRMS (ESI) *m*/*z*: calcd for $C_{13}H_{16}NO_6$ [M + H], 282.0978; found, 282.0969.

*3-(3-Methoxyphenethyl)-1,4,2-dioxazol-5-one (**1r**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (1.2 g, 87%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.90 (ddd, *J* = 2.0, 6.8, 14.6 Hz, 2H), 2.98 (ddd, *J* = 2.0, 6.8, 14.6 Hz, 2H), 3.78 (s, 3H), 6.73 (t, *J* = 2.0 Hz, 1H), 6.79 (td, *J* = 2.4, 7.8 Hz, 2H), 7.23 (t, *J* = 7.8 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 26.5, 30.4, 55.2, 112.3, 114.1, 120.5, 130.0, 139.7, 154.1, 160.0, 166.0.

*3-(2-(Naphthalen-1-yl)ethyl)-1,4,2-dioxazol-5-one (**1s**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; white solid (570 mg, 75%); mp 68−70 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.99 (t, *J* = 8.0 Hz, 2H), 3.43 (t, *J* = 8.0 Hz, 2H), 7.30 (d, *J* = 6.8 Hz, 1H), 7.39 (d, *J* = 7.8 Hz, 1H), 7.41−7.56 (m, 2H), 7.76 (d, *J* = 8.0 Hz, 1H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 25.9, 27.7, 122.7, 125.6, 126.0, 126.4, 126.7, 128.1, 129.2, 131.2, 134.0, 134.1, 154.1, 166.0.

*3-(4-Methoxyphenethyl)-1,4,2-dioxazol-5-one (**3a**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (790 mg, 80%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.90 (td, *J* = 1.2, 6.8 Hz, 2H), 2.98 (td, *J* = 1.2, 6.8 Hz, 2H), 3.79 (s, 3H), 6.86 (d, *J* = 8.6 Hz, 2H), 7.11 (d, *J* = 8.6 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 27.0, 29.7, 55.3, 114.3, 129.2, 130.0, 154.1, 158.7, 165.9.

*3-(4-Methylphenethyl)-1,4,2-dioxazol-5-one (**3b**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (390 mg, 68%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.31 (s, 3H), 2.86−2.90 (m, 2H), 2.95−2.99 (m, 2H), 7.07 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 21.1, 26.8, 30.1, 128.1, 129.6, 135.1, 136.8, 154.1, 166.0.

*tert-Butyl (4-(2-(5-oxo-1,4,2-dioxazol-3-yl)ethyl)phenyl)-carbamate (**3c**).* Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; white solid (330 mg, 77%); mp 108−110 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.51 (s, 9H), 2.89 (d, *J* = 7.2 Hz, 2H), 2.97 (d, *J* = 7.2 Hz, 2H), 6.65 (br s, 1H), 7.10 (d, *J* = 8.2 Hz, 2H), 7.32 (d, *J* = 8.2 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 26.7, 28.3, 29.8, 80.6, 119.0, 128.7, 132.5, 137.4, 152.8, 154.1, 165.9; HRMS (ESI) *m*/*z*: calcd for $C_{15}H_{19}N_2O_5$ [M + H], 307.1294; found, 307.1289.

*3-(2-(4-Methoxyphenyl)-2-phenylethyl)-1,4,2-dioxazol-5-one (**3d**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (210 mg, 71%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 3.25 (d, *J* = 8.0 Hz, 2H), 3.71 (s, 3H), 4.39 (t, *J* = 8.0 Hz, 1H), 6.82 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H), 7.20 (d, *J* = 7.2 Hz, 3H), 7.28 (t, *J* = 7.2 Hz, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 31.3, 46.0, 55.3, 114.4, 127.3, 127.4, 128.6, 129.0, 133.4, 141.8, 154.0, 158.8, 165.2.

*3-(2-Methoxyphenethyl)-1,4,2-dioxazol-5-one (**3e**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (486 mg, 88%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.87 (t, *J* = 7.2 Hz, 2H), 2.99 (t, *J* = 7.2 Hz, 2H), 3.80 (s, 3H), 6.84−6.90 (m, 2H), 7.10 (dd, *J* = 1.6, 7.2 Hz, 1H), 7.23 (td, *J* = 1.6, 8.0 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 25.1, 26.2, 55.2, 110.5, 120.8, 126.4, 128.6, 130.1, 154.4, 157.5, 166.5; HRMS

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

(ESI) m/z: calcd for $C_{11}H_{12}NO_4$ [M + H], 222.0766; found, 222.0756.

*3-(2-Methylphenethyl)-1,4,2-dioxazol-5-one (**3f**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; white solid (460 mg, 58%); mp 81−83 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.34 (s, 3H), 2.90 (t, J = 8.0 Hz, 2H), 3.03 (t, J = 8.0 Hz, 2H), 7.12−7.21 (m, 4H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 19.2, 25.4, 28.0, 126.5, 127.4, 128.5, 130.8, 135.8, 136.2, 154.0, 166.0.

*3-(4′-Methyl-[1,1′-biphenyl]-2-yl)-1,4,2-dioxazol-5-one (**3g**).* Prepared according to general procedure B; eluent: petroleum ether/ethyl acetate = 10:1; white solid (310 mg, 52%); mp 59−61 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.25 (s, 3H), 7.07 (q, J = 8.0 Hz, 4H), 7.33 (dd, J = 7.8, 12.0 Hz, 2H), 7.50 (t, J = 7.6 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 21.3, 119.0, 127.7, 128.4, 129.4, 129.9, 131.5, 133.2, 136.1, 138.3, 143.0, 153.9, 164.8; HRMS (ESI) m/z: calcd for $C_{15}H_{12}NO_3$ [M + H], 254.0817; found, 254.0807.

*3-(4-Methoxybenzyl)-1,4,2-dioxazol-5-one (**3h**).*[7a] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (490 mg, 86%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 3.78 (s, 3H), 3.84 (s, 2H), 6.88 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 30.3, 55.3, 114.6, 122.3, 130.2, 154.1, 159.6, 165.7.

*3-(4-Hydroxyphenethyl)-1,4,2-dioxazol-5-one (**5a**).*[10] Prepared according to general procedure C; eluent: petroleum ether/ethyl acetate = 10:1; white solid (350 mg,81%); mp 75−77 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.88 (d, J = 7.4 Hz, 2H), 2.95 (d, J = 6.8 Hz, 2H), 5.05 (s, 1H), 6.78 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 27.0, 29.7, 115.7, 129.5, 130.2, 154.1, 154.6, 165.9.

*3-(4-Hydroxy-3-methoxyphenethyl)-1,4,2-dioxazol-5-one (**5b**).*[10] Prepared according to general procedure D; eluent: petroleum ether/ethyl acetate = 10:1; white solid (74 mg, 66%); mp 93−95 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.87−2.95 (m, 4H), 3.86 (s, 3H), 5.68 (s, 1H), 6.68 (d, J = 6.6 Hz, 2H), 6.84 (d, J = 8.4 Hz, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 27.0, 30.2, 55.9, 110.8, 114.7, 120.9, 130.0, 144.7, 146.7, 154.1, 166.0.

*3-(4-Hydroxy-2-methoxyphenethyl)-1,4,2-dioxazol-5-one (**5c**).*[10] Prepared according to general procedure E; eluent: petroleum ether/ethyl acetate = 10:1; white solid (59 mg, 17%); mp 95−97 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.79−2.87 (m, 2H), 2.88−2.95 (m, 2H), 3.75 (s, 3H), 5.61 (s, 1H), 6.34 (d, J = 8.0 Hz, 1H), 6.40 (s, 1H), 6.93 (d, J = 8.0 Hz, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 25.4, 25.7, 55.3, 99.1, 107.0, 118.5, 130.6, 154.6, 156.2, 158.5, 166.6.

*3-(4-Hydroxy-3,5-dimethoxyphenethyl)-1,4,2-dioxazol-5-one (**5d**).* Prepared according to general procedure E; eluent: petroleum ether/ethyl acetate = 10:1; white solid (70 mg, 17%); mp 69−72 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.93 (s, 4H), 3.87 (s, 6H), 5.50 (s, 1H), 6.41 (s, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 27.0, 30.7, 56.4, 105.0, 129.1, 133.9, 147.3, 154.0, 165.9; HRMS (ESI) m/z: calcd for $C_{12}H_{14}NO_6$ [M + H], 282.0978; found, 282.0969.

*3-(4-Hydroxy-3,5-dimethylphenethyl)-1,4,2-dioxazol-5-one (**5e**).*[10] Prepared according to general procedure E; eluent: petroleum ether/ethyl acetate = 10:1; white solid (120 mg, 34%); mp 96−98 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.21 (s, 6H), 2.86 (s, 4H), 4.76 (s, 1H), 6.79 (s, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 15.9, 27.0, 29.7, 123.6, 128.3, 129.6, 151.3, 154.2, 166.2.

*3-(3,5-Dibromo-4-hydroxyphenethyl)-1,4,2-dioxazol-5-one (**5f**).* Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; white solid (170 mg, 22%); mp 88−90 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.93 (s, 4H), 5.90 (s, 1H), 7.32 (s, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 26.5, 28.8, 110.1, 131.8, 132.6, 148.6, 153.8, 165.4; HRMS (ESI) m/z: calcd for $C_{10}H_7Br_2NO_4Na$ [M + Na], 385.8640; found, 385.8639.

*2-(2-(4-Hydroxyphenyl)-1-(5-oxo-1,4,2-dioxazol-3-yl)ethyl) Isoindoline-1,3-dione (**5g**).*[10] Prepared according to general procedure A; eluent: petroleum ether/ethyl acetate = 10:1; colorless oil (70 mg, 66%); ^{1}H NMR (400 MHz, $CDCl_3$): δ 3.42−3.61 (m, 2H), 5.06 (br s, 1H), 5.53 (dd, J = 6.0, 10.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 7.73−7.78 (m, 2H), 7.80−7.86 (m, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 33.0, 46.6, 115.8, 124.0, 126.3, 130.3, 131.0, 134.8, 153.3, 155.0, 163.7, 166.7.

*3-(2-Hydroxy-4-methoxyphenethyl)-1,4,2-dioxazol-5-one (**5h**).*[10] Prepared according to general procedure E; eluent: petroleum ether/ethyl acetate = 10:1; white solid (120 mg, 37%); mp 70−73 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.87−2.96 (m, 4H), 3.73 (s, 3H), 5.90 (s, 1H), 6.32 (s, 1H), 6.42 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 25.2, 25.3, 55.4, 102.2, 105.9, 117.3, 131.1, 154.6, 154.7, 159.7, 166.6.

Preparation of the Catalysts. Catalysts **cat-1**, **cat-1**, **cat-3**, **cat-4**, **cat-5**, **cat-6**, and **cat-7** were prepared according to our previous publications. The procedure for the preparation of **cat-8** is described as follows.

Preparation of the Ligand. To a solution of 2-formylisonicotinonitrile (150 mg, 1.1 mmol) in DCM (20 mL) was dropwise added ethylenediamine (0.09 mL, 1.3 mmol). The mixture was stirred for 1 h and then cooled to 0 °C. *N*-Bromosuccinimide (240 mg, 1.3 mmol) was added, and the mixture was stirred overnight. The reaction mixture was washed with 5% NaOH solution (10 mL) and then saturated $Na_2S_2O_3$ solution (10 mL). The organic phase was dried with Na_2SO_4 and concentrated to give the ligand as a brown solid (170 mg, 99%). This product was directly used in the next step without further purification.

Synthesis of Cat-8. To a solution of ligand (150 mg, 0.87 mmol) in 10 mL of DCM was added the powder of $[Cp^*IrCl_2]_2$ (330 mg, 0.4 mmol). The resultant orange solution was stirred overnight. DCM was removed under reduced pressure, and the resultant yellow solid was dissolved in a minimum amount of DCM. Then, a large amount of EtOAc was added slowly to precipitate an orange solid as the desired product, which was isolated by reduced pressure filtration and further dried under vacuum at room temperature to give **cat-8** as red powder (460 mg, 93%).

Cat-8. Orange powder (460 mg, 93%). mp > 350 °C; ^{1}H NMR (400 MHz, D_2O): δ 1.63 (s, 15H), 3.87 (s, 1H), 4.00 (t, J = 20.9 Hz, 2H), 4.70 (s, 1H), 8.06 (dd, J = 1.6, 5.8 Hz, 1H), 8.27 (d, J = 1.0 Hz, 1H), 9.05 (d, J = 5.8 Hz, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, D_2O): δ 8.1, 46.0, 52.4, 89.5, 114.9, 123.2, 127.4, 132.1, 147.4, 153.1, 168.2; HRMS (ESI): for $C_{19}H_{23}ClIrN_4$ $(M)^+$, 535.1235 (calcd); found, 535.1220.

General Procedures of the Ir-Catalyzed Intramolecular Amidation of Dioxazolones. To a 10 mL flask equipped with a magnetic stirring bar were added 1,4,2-dioxazol-5-one (0.1−0.5 mmol), **cat-3** (2 mol %), $NaBAr^F{}_4$ (4 mol %), and DCM (3 mL). The reaction mixture was stirred in a preheated oil bath at 40 °C for 12 h. After the solvent was removed, the residue was purified by silica chromatography (eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1).

Procedures for the Gram-Scale Reaction of 1p to 2p. To a 100 mL flask equipped with a magnetic stirring bar were added 1,4,2-dioxazol-5-one **1p** (8.0 mmol), **cat-3** (2 mol %), $NaBAr^F{}_4$ (4 mol %), and HFIP (50 mL). The reaction mixture was stirred in a preheated oil bath at 60 °C for 24 h until the reaction was complete. After the solvent was removed, the residue was purified by silica chromatography (eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1) to give **2p** as a white solid (1.52 g, 7.3 mmol), and the yield was 91%.

Procedures for the Gram-Scale Reaction of 5a to 6a. To a 100 mL flask equipped with a magnetic stirring bar were added 1,4,2-dioxazol-5-one **5a** (6.3 mmol), **cat-3** (2 mol %), $NaBAr^F{}_4$ (4 mol %), and DCM (50 mL). The reaction mixture was stirred in a preheated oil bath at 40 °C for 24 h until the reaction was complete. After the solvent was removed, the residue was purified by silica chromatography (eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1) to give **6a** as a white solid (895 mg, 5.5 mmol), and the yield was 87%.

*5-(Thiophen-2-yl)pyrrolidin-2-one (**2a**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; light yellow solid (35 mg, 89%); mp 100−103 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.07−2.17 (m, 1H), 2.34−2.44 (m, 1H), 2.46−2.54 (m, 1H), 2.56−2.64 (m, 1H), 5.02 (t, J = 6.6 Hz, 1H), 6.62 (s, 1H), 6.93−7.02 (m,

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

2H), 7.24 (d, J = 4.0 Hz, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 30.2, 31.2, 54.0, 124.1, 124.8, 127.0, 146.5, 178.1.

*5-Phenylpyrrolidin-2-one (**2b**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (26 mg, 81%); mp 98−101 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 1.91−2.00 (m, 1H), 2.35−2.49 (m, 2H), 2.50−2.59 (m, 1H), 4.75 (t, J = 7.0 Hz, 1H), 6.64 (br s, 1H), 7.23−7.30 (m, 3H), 7.34−7.38 (m, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 31.4, 31.3, 58.1, 125.6, 127.9, 128.9, 142.5, 178.8.

*5-(4-Methoxyphenyl)pyrrolidin-2-one (**2c**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (61 mg, 76%); mp 118−120 °C;^1H NMR (400 MHz, $CDCl_3$): δ 1.87−1.95 (m, 1H), 2.32−2.46 (m, 2H), 2.47−2.58 (m, 1H), 3.79 (s, 3H), 4.69 (t, J = 7.0 Hz, 1H), 6.79 (s, 1H), 6.88 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 30.6, 31.4, 55.3, 57.7, 114.2, 126.9, 134.6, 159.2, 178.8.

*5-(p-Tolyl)pyrrolidin-2-one (**2d**).*[9b] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (26 mg, 51%); mp 112−115 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 1.93−2.00 (m, 1H), 2.35 (s, 3H), 2.39−2.47 (m, 2H), 2.51−2.58 (m, 1H), 4.72 (t, J = 7.0 Hz, 1H), 5.90 (br s, 1H), 7.18 (s, 4H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 21.1, 30.4, 31.4, 57.9, 125.6, 129.5, 137.6, 139.5, 178.6.

*5-Vinylpyrrolidin-2-one (**2e**).*[9c] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; colorless oil (15 mg, 56%); ^1H NMR (400 MHz, $CDCl_3$): δ 1.77−1.86 (m, 1H), 2.25−2.42 (m, 3H), 4.16 (q, J = 6.4 Hz, 1H), 5.13 (d, J = 10.2 Hz, 1H), 5.22 (d, J = 17.2 Hz, 1H), 5.75−5.85 (m, 1H), 6.12 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 28.0, 29.9, 56.7, 115.7, 138.7, 178.5.

*Hexahydrocyclopenta[b]pyrrol-2(1H)-one (**2f**).*[9c] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; colorless oil (27 mg, 76%); ^1H NMR (400 MHz, $CDCl_3$): δ 1.49−1.55 (m, 1H), 1.60−1.73 (m, 4H), 1.74−1.82 (m, 1H), 2.05 (dd, J = 3.6, 17.6 Hz, 1H), 2.63 (dd, J = 10.2 Hz, 1H), 2.78−2.86 (m, 1H), 4.09−4.13 (m, 1H), 6.52 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 23.7, 34.3, 34.5, 37.2, 38.0, 59.3, 178.5.

*1-Azaspiro[4.5]decan-2-one (**2g**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (51 mg, 83%); mp 120−122 °C; ^1H NMR (400 MHz, $CDCl_3$): δ1.42 (s, 2H), 1.47−1.62 (m, 8H), 1.89 (t, J = 8.0 Hz, 2H), 2.38 (t, J = 8.0 Hz, 2H), 7.07 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 23.0, 25.2, 30.0, 32.7, 38.3, 59.5, 177.5.

*5,5-Dimethylpyrrolidin-2-one (**2h**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; colorless oil (30 mg, 84%); ^1H NMR (400 MHz, $CDCl_3$): δ 1.29 (s, 6H), 1.92 (t, J = 8.0 Hz, 2H), 2.42 (t, J = 8.0 Hz, 2H), 7.10 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 29.2, 30.7, 35.3, 56.6, 177.1.

*3-Phenylisoindolin-1-one (**2i**).*[9d] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (29 mg, 99%); mp 209−212 °C; ^1H NMR (400 MHz, DMSO-d_6): δ 5.73 (s, 1H), 7.30 (t, J = 8.0 Hz, 4H), 7.36 (t, J = 7.2 Hz, 2H), 7.48 (t, J = 7.2 Hz, 1H), 7.54 (t, J = 7.2 Hz, 1H), 7.72 (d, J = 7.2 Hz, 1H), 9.07 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, DMSO-d_6): δ 60.0, 123.3, 123.9, 127.0, 128.4, 128.6, 129.2, 131.8, 132.3, 140.1, 148.6, 170.1.

*3,3-Dimethylisoindolin-1-one (**2j**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (39 mg, 99%); mp 152−154 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 1.58 (s, 6H), 7.41 (d, J = 7.6 Hz, 1H), 7.44 (td, J = 0.4, 7.4 Hz, 1H), 7.56 (td, J = 0.8, 7.4 Hz, 1H), 7.83 (d, J = 7.6 Hz, 1H), 8.08 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 27.7, 59.2, 120.9, 123.8, 127.9, 130.8, 132.0, 153.2, 170.1.

*3-Methylisoindolin-1-one (**2k**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (29 mg, 71%); mp 102−104 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 1.52 (d, J = 6.8 Hz, 3H), 4.72 (q, J = 6.8 Hz, 1H), 7.46 (q, J = 7.4 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.85 (d, J = 7.4 Hz, 1H), 8.18 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 20.2, 52.8, 122.2, 123.6, 128.0, 131.7, 131.9, 149.0, 171.3.

*3-Benzylisoindolin-1-one (**2l**).*[13] Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (22 mg, 71%); mp 128−130 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 2.79 (dd, J = 10.0, 12.4 Hz, 1H), 3.24 (dd, J = 4.2, 13.6 Hz, 1H), 4.80 (t, J = 7.4 Hz, 1H), 6.45 (br s, 1H), 7.20−2.25 (m, 2H), 7.30 (d, J = 6.6 Hz, 1H), 7.34 (d, J = 7.4 Hz, 3H), 7.48 (t, J = 7.4 Hz, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.84 (d, J = 7.4 Hz, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 41.4, 58.0, 122.7, 123.9, 127.2, 128.4, 128.9, 129.3, 131.8, 131.9, 137.0, 146.9, 170.4.

*2-(((3aR,7aR)-2-Oxooctahydro-3aH-indol-3a-yl)methyl)-isoindoline-1,3-dione (**2m**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (16 mg, 92%); mp 173−176 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 1.45−1.59 (m, 6H), 1.68−1.75 (m, 1H), 1.82−1.91 (m, 1H), 2.01 (d, J = 16.4 Hz, 1H), 2.49 (d, J = 16.4 Hz, 1H), 3.58 (s, 1H), 3.79 (s, 2H), 6.04 (s, 1H), 7.75 (d, J = 2.2 Hz, 2H), 7.86 (d, J = 2.2 Hz, 2H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 19.8, 21.1, 26.3, 30.7, 42.4, 42.9, 43.2, 55.4, 123.5, 131.8, 134.3, 168.9, 176.8.

*5-Methoxyindolin-2-one (**2n**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (36 mg, 65%); mp 140−142 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 3.52 (s, 2H), 3.78 (s, 3H), 6.77 (q, J = 8.2 Hz, 2H), 6.85 (s, 1H), 8.50 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 36.8, 55.8, 110.2, 111.7, 112.5, 126.7, 136.2, 155.7, 178.2.

*7-Methoxyindolin-2-one (**2n′**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (9 mg, 16%); mp 139−141 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 3.56 (s, 2H), 3.88 (s, 3H), 6.83 (dd, J = 7.4, 17.2 Hz, 2H), 6.98 (t, J = 7.8 Hz, 1H), 8.08 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 36.8, 55.7, 110.2, 117.0, 122.8, 126.0, 131.3, 143.8, 176.6.

*5,6-Dimethoxyindolin-2-one (**2o**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (22 mg, 95%); mp 170−173 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 3.50 (s, 2H), 3.85 (s, 3H), 3.86 (s, 3H), 6.55 (s, 1H), 6.84 (s, 1H), 8.77 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 36.5, 56.3, 56.8, 95.7, 109.7, 115.9, 136.1, 145.0, 149.4, 178.4.

*6,7-Dimethoxy-3,4-dihydroquinolin-2(1H)-one (**2p**).*[7a] Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (19 mg, 98%); mp 123−125 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 2.62 (t, J = 7.4 Hz, 2H), 2.89 (t, J = 7.4 Hz, 2H), 3.85 (s, 3H), 3.87 (s, 3H), 6.53 (s, 1H), 6.84 (s, 1H), 8.46 (s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 25.0, 30.9, 56.2, 56.4, 100.6, 111.7, 114.8, 130.8, 144.7, 148.4, 172.3.

*6,7,8-Trimethoxy-3,4-dihydroquinolin-2(1H)-one (**2q**).* Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (50 mg, 99%); mp 118−120 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 2.61 (t, J = 7.4 Hz, 2H), 2.91 (t, J = 7.4 Hz, 2H), 3.83 (s, 3H), 3.86 (s, 3H), 3.92 (s, 3H), 6.48 (s, 1H), 7.75 (s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 25.6, 30.8, 56.4, 61.0, 61.1, 106.9, 118.3, 124.2, 140.2, 140.9, 148.8, 170.0; HRMS (ESI) m/z: calcd for $C_{12}H_{16}NO_4$ [M + H], 238.1079; found, 238.1070.

*6-Methoxy-3,4-dihydroquinolin-2(1H)-one (**2r**).*[10] Eluent: petroleum ether/ethyl acetate/methanol, 10:10:1−5:5:1; white solid (39 mg, 82%); mp 125−127 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 2.62 (t, J = 8.0 Hz, 2H), 2.94 (t, J = 8.0 Hz, 2H), 3.78 (s, 3H), 6.69−6.72 (m, 2H), 6.76−6.79 (m, 1H), 9.13 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 25.7, 30.6, 55.6, 112.4, 113.8, 116.3, 125.0, 130.9, 155.6, 171.8.

*1,4-Dihydrobenzo[f]quinolin-3(2H)-one (**2s**).* Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (19 mg, 96%); mp 233−236 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 2.80 (t, J = 7.8 Hz, 2H), 3.35 (t, J = 7.8 Hz, 2H), 7.06 (d, J = 8.6 Hz, 1H), 7.39 (t, J = 7.2 Hz, 1H), 7.53 (t, J = 7.2 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 9.10 (s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$): δ 21.1, 30.3, 116.1, 116.8, 122.6, 124.2, 127.0, 128.3, 128.8, 130.5, 131.5, 134.6, 171.9; HRMS (ESI) m/z: calcd for $C_{13}H_{12}NO$ [M + H], 198.0919; found, 198.0910.

*6-Methyl-3,4-dihydroquinolin-2(1H)-one (**4b**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (45 mg, 87%); mp 126−128 °C; ^1H NMR (400 MHz, $CDCl_3$): δ 2.29 (s, 3H), 2.62 (t, J = 8.0 Hz, 2H), 2.93 (t, J = 8.0 Hz, 2H), 6.72 (d, J = 8.4 Hz, 1H), 6.98 (s, 2H), 8.95 (br s, 1H); $^{13}C\{^1H\}$ NMR (100 MHz,

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440

$CDCl_3$): δ 20.8, 25.4, 30.8, 115.4, 123.5, 127.9, 128.6, 132.6, 134.9, 172.0.

*tert-Butyl (2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)carbamate (**4c**).* Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (19 mg, 37%); mp 187−189 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.51 (s, 9H), 2.60 (t, *J* = 8.0 Hz, 2H), 2.93 (t, *J* = 7.2 Hz, 2H), 6.66 (br s, 1H), 6.75 (d, *J* = 8.4 Hz, 1H), 7.02 (dd, *J* = 2.0, 10.4 Hz, 1H), 7.35 (s, 1H), 9.23 (br s, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 25.5, 28.4, 30.6, 80.6, 115.8, 118.0, 118.8, 124.4, 132.9, 133.7, 153.1, 172.0; HRMS (ESI) *m*/*z*: calcd for $C_{14}H_{19}N_2O_3$[M + H], 263.1396; found, 263.1396.

*6-Methoxy-4-phenyl-3,4-dihydroquinolin-2(1H)-one (**4d**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (16 mg, 93%); mp 150−153 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.84−2.95 (m, 2H), 3.69 (s, 3H), 4.25 (t, *J* = 7.2 Hz, 1H), 6.48 (s, 1H), 6.74 (d, *J* = 8.4 Hz, 1H), 6.80 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 7.6 Hz, 2H), 7.27 (d, *J* = 8.4 Hz, 1H), 7.33 (t, *J* = 7.6 Hz, 2H), 8.65 (s, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 38.4, 42.3, 55.5, 112.8, 114.4, 116.5, 127.3, 127.8, 128.1, 129.0, 130.6, 141.3, 155.8, 170.4.

*8-Methoxy-3,4-dihydroquinolin-2(1H)-one (**4e**).* Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (39 mg, 51%); mp 55−58 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.61 (t, *J* = 8.0 Hz, 2H), 2.96 (t, *J* = 7.2 Hz, 2H), 3.86 (s, 3H), 6.76 (dd, *J* = 2.8, 8.4 Hz, 2H), 6.93 (t, *J* = 8.0 Hz, 1H), 7.83 (br s, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 25.4, 30.7, 55.8, 109.0, 119.9, 122.7, 124.0, 126.5, 145.8, 170.4; HRMS (ESI): for $C_{10}H_{12}NO_2$(M + H), 178.0868 (calcd); found, 178.0863.

*8-Methyl-3,4-dihydroquinolin-2(1H)-one (**4f**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (9 mg, 37%); mp 113−115 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.22 (s, 3H), 2.63 (t, *J* = 7.2 Hz, 2H), 2.96 (t, *J* = 7.2 Hz, 2H), 6.91 (t, *J* = 7.4 Hz, 1H), 7.03 (d, *J* = 7.4 Hz, 2H), 7.37 (br s, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 16.6, 25.7, 30.8, 122.5, 122.7, 123.7, 125.8, 129.0, 135.5, 171.3.

*2-Methylphenanthridin-6(5H)-one (**4g**).*[14] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (14 mg, 56%); mp 234−236 °C; ^{1}H NMR (400 MHz, MeOD-d_4): δ 2.41 (s, 3H), 7.28 (q, *J* = 8.4 Hz, 2H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.83 (t, *J* = 8.0 Hz, 1H), 8.18 (s, 1H), 8.32 (d, *J* = 7.8 Hz, 1H), 8.47 (d, *J* = 8.0 Hz, 1H), 11.60 (s, 1H); ^{13}C{^{1}H} NMR (100 MHz, MeOD-d_4): δ 20.7, 116.0, 117.4, 122.5, 123.0, 125.7, 127.5, 127.7, 130.5, 131.2, 132.6, 134.2, 134.4, 160.7.

*1-Azaspiro[4.5]deca-6,9-diene-2,8-dione (**6a**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (36 mg, 99%); mp 170−174 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.26 (t, *J* = 8.0 Hz, 2H), 2.56 (t, *J* = 8.0 Hz, 2H), 6.23 (d, *J* = 9.6 Hz, 2H), 6.84 (d, *J* = 9.6 Hz, 2H), 6.98 (s, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 29.5, 32.2, 57.5, 128.8, 149.4, 177.7, 184.4.

*7-Methoxy-1-azaspiro[4.5]deca-6,9-diene-2,8-dione (**6b**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (28 mg, 97%); mp 219−221 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.31 (q, *J* = 7.2 Hz, 2H), 2.58 (t, *J* = 8.0 Hz, 2H), 3.70 (s, 3H), 5.73 (s, 1H), 6.24 (d, *J* = 9.8 Hz, 1H), 6.41 (s, 1H), 6.85 (dd, *J* = 1.8, 9.8 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 29.6, 33.4, 55.1, 59.1, 116.5, 127.7, 149.9, 150.7, 177.1, 179.9.

*6-Methoxy-1-azaspiro[4.5]deca-6,9-diene-2,8-dione (**6c**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (19 mg, 99%); mp 175−177 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.19−2.25 (m, 1H), 2.33−2.39 (m, 1H), 2.42−2.49 (m, 1H), 2.63−2.70 (m, 1H), 3.78 (s, 3H), 5.53 (s, 1H), 6.17 (d, *J* = 10.0 Hz, 1H), 6.27 (s, 1H), 6.58 (d, *J* = 10.0 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 29.8, 32.2, 56.1, 58.8, 101.4, 128.2, 145.9, 174.6, 178.6, 186.4.

*7,9-Dimethoxy-1-azaspiro[4.5]deca-6,9-diene-2,8-dione (**6d**).* Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (19 mg, 98%); mp 252−255 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.36 (t, *J* = 8.0 Hz, 2H), 2.60 (t, *J* = 8.0 Hz, 2H), 3.70 (s, 6H), 5.55 (s, 1H), 5.76 (s, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 29.7, 34.8, 55.5, 57.7, 117.0, 150.1, 175.6, 176.5; HRMS (ESI) *m*/*z*: calcd for $C_{11}H_{14}NO_4$ [M + H], 224.0923; found, 224.0916.

*7,9-Dimethyl-1-azaspiro[4.5]deca-6,9-diene-2,8-dione (**6e**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (39 mg, 99%); mp 178−182 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 1.90 (s, 6H), 2.21 (t, *J* = 8.0 Hz, 2H), 2.53 (t, *J* = 8.0 Hz, 2H), 6.16 (s, 1H), 6.59 (s, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 15.9, 29.6, 32.5, 57.5, 135.2, 144.4, 177.4, 185.9.

*7,9-Dibromo-1-azaspiro[4.5]deca-6,9-diene-2,8-dione (**6f**).* Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (8 mg, 92%); mp 219−221 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.39 (t, *J* = 8.0 Hz, 2H), 2.58 (t, *J* = 8.0 Hz, 2H), 5.93 (s, 1H), 7.31 (s, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 28.8, 31.8, 61.7, 122.7, 149.5, 171.4, 176.0; HRMS (ESI) *m*/*z*: calcd for $C_{19}H_8Br_2NO_2$ [M + H], 319.8922; found, 319.8917.

*3-(1,3-Dioxoisoindolin-2-yl)-1-azaspiro[4.5]deca-6,9-diene-2,8-dione (**6g**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (30 mg, 97%); mp 276−280 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.58 (t, *J* = 11.4 Hz, 1H), 2.74 (t, *J* = 11.4 Hz, 1H), 5.18 (t, *J* = 10.0 Hz, 1H), 6.27 (dd, *J* = 10.4, 15.0 Hz, 2H), 6.67 (s, 1H), 6.94 (d, *J* = 10.0 Hz, 1H), 7.12 (d, *J* = 10.0 Hz, 1H), 7.74−7.80 (m, 2H), 7.85−7.91 (m, 2H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 35.7, 48.2, 54.5, 123.7, 128.7, 129.5, 131.7, 134.6, 148.3, 149.2, 167.3, 171.5, 184.1.

*8-Methoxy-1-azaspiro[4.5]deca-7,9-diene-2,6-dione (**7a**).*[10] Eluent: petroleum ether/ethyl acetate/methanol = 10:10:1−5:5:1; white solid (10 mg, 52%); mp 120−123 °C; ^{1}H NMR (400 MHz, $CDCl_3$): δ 2.01−2.07 (m, 1H), 2.25−2.32 (m, 1H), 2.35−2.40 (m, 1H), 2.63−2.70 (m, 1H), 3.80 (s, 3H), 5.42 (d, *J* = 1.2 Hz, 1H), 5.89 (s, 1H), 6.13 (dd, *J* = 1.6, 10.0 Hz, 1H), 6.39 (d, *J* = 10.0 Hz, 1H); ^{13}C{^{1}H} NMR (100 MHz, $CDCl_3$): δ 28.3, 32.4, 56.2, 64.1, 97.7, 123.0, 143.3, 170.5, 179.2, 199.5.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.0c00157.

Experimental procedures, full characterization of products, and NMR spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Jitian Liu − *Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 250012 Jinan, Shandong, P.R. China; College of Chemistry and Molecule Engineering, Peking University, 100871 Beijing, P. R. China;* orcid.org/0000-0002-3346-5440; Email: liujt@sdu.edu.cn

Xiaoxun Li − *Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 250012 Jinan, Shandong, P.R. China*; Email: xli@sdu.edu.cn

Authors

Wenjing Ye − *School of Pharmacy, University of Wisconsin−Madison, Madison, Wisconsin 53705, United States; Key Laboratory of Structure Based Drug Design and Discovery, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, P. R. China*

Shuojin Wang − *School of Pharmacy, Hainan Medical University, Haikou 571199, P. R. China*

Junrong Zheng − *College of Chemistry and Molecule Engineering, Peking University, 100871 Beijing, P. R. China;* orcid.org/0000-0002-4472-8576

Weiping Tang − *School of Pharmacy, University of Wisconsin−Madison, Madison, Wisconsin 53705, United States;* orcid.org/0000-0002-0039-3196

Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.joc.0c00157

Author Contributions

The manuscript was written through contributions of all authors.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (NSFC) (NSFC-21673004); X.L. gratefully acknowledges the National Natural Science Foundation of China (21901142), the Natural Science Foundation of Shandong Province (ZR2019QB001), the Key Research and Development Program of Shandong Province (2017CXGC1401), the Natural Science Foundation of Jiangsu Province (BK20180227), and the Fundamental Research Funds of Shandong University (21310088963023, 2020QNQT007, 2020QNQT009) for generous financial support. W.Y. thanks Chinese Scholarship Council for financial support of the visiting scholarship at UW-Madison. S.W. thanks HaiNan Provincial Natural Science Foundation of China (20152023).

■ REFERENCES

(1) (a) Tan, D. Q.; Martin, K. S.; Fettinger, J. C.; Shaw, J. T. Ammonia synthons for the multicomponent assembly of complex γ-lactams. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, 6781−6786. (b) Okazaki, Y.; Ishizuka, A.; Ishihara, A.; Nishioka, T.; Iwamura, H. New Dimeric Compounds of Avenanthramide Phytoalexin in Oats. *J. Org. Chem.* **2007**, *72*, 3830−3839. (c) Masse, C. E.; Morgan, A. J.; Adams, J.; Panek, J. S. Syntheses and Biological Evaluation of (+)-Lactacystin and Analogs. *Eur. J. Org. Chem.* **2000**, 2513−2528.

(2) (a) Vintonyak, V. V.; Warburg, K.; Kruse, H.; Grimme, S.; Hübel, K.; Rauh, D.; Waldmann, H. Identification of Thiazolidinones Spiro-Fused to Indolin-2-ones as Potent and Selective Inhibitors of the Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. *Angew. Chem., Int. Ed.* **2010**, *49*, 5902−5905. (b) Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). *Bioorg. Med. Chem.* **2009**, *17*, 2175−2180. (c) Stuk, T. L.; Assink, B. K.; Bates, R. C.; Erdman, D. T.; Fedij, V.; Jennings, S. M.; Lassig, J. A.; Smith, R. J.; Smith, T. L. An Efficient and Cost-Effective Synthesis of Pagoclone. *Org. Process Res. Dev.* **2003**, *7*, 851−855. (d) Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus Salinospora. *Angew. Chem., Int. Ed.* **2003**, *42*, 355−357. (e) Duan, J. J.-W.; Chen, L.; Wasserman, Z. R.; Lu, Z.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Hardman, K. D.; Magolda, R. L.; Newton, R. C.; Christ, D. D.; Wexler, R. R.; Decicco, C. P. Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure-Activity Relationships. *J. Med. Chem.* **2002**, *45*, 4954−4957. (f) Bergmann, R.; Gericke, R. Synthesis and Antihypertensive Activity of 4-(l,2-Dihydro-2-oxo-l-pyridyl)-2H-l-benzopyrans and Related Compounds, New Potassium Channel Activators. *J. Med. Chem.* **1990**, *33*, 492−504.

(3) (a) Li, X.-S.; Zhao, L.-L.; Wang, X.-K.; Cao, L. L.; Shi, X.-Q.; Zhang, R.; Qi, J. Enantioselective [3+2] Annulation of Enals with 2-Aminoacrylates Catalyzed by N-Heterocyclic Carbene. *Org. Lett.* **2017**, *19*, 3943−3946. (b) Di Maso, M. J.; Nepomuceno, G. M.; Peter, M. A. S.; Gitre, H. H.; Martin, K. S.; Shaw, J. T. Synthesis of (±)-Bisavenanthramide B-6 by an Anionic Anhydride Mannich Reaction. *Org. Lett.* **2016**, *18*, 1740−1743. (c) Huang, X.; Liu, M.; Pham, K.; Zhang, X.; Yi, W.-B.; Jasinski, J. P.; Zhang, W. Organocatalytic One-Pot Asymmetric Synthesis of Thiolated Spiro-γ-lactam Oxindoles Bearing Three Stereocenters. *J. Org. Chem.* **2016**, *81*, 5362−5369. (d) Nagamoto, M.; Yanagi, T.; Nishimura, T.; Yorimitsu, H. Asymmetric Cyclization of N-Sulfonyl Alkenyl Amides Catalyzed by Iridium/Chiral Diene Complexes. *Org. Lett.* **2016**, *18*, 4474−4477. (e) Shuler, S. A.; Yin, G.; Krause, S. B.; Vesper, C. M.; Watson, D. A. Synthesis of Secondary Unsaturated Lactams via an Aza-Heck Reaction. *J. Am. Chem. Soc.* **2016**, *138*, 13830−13833. (f) Zhou, Z.; Liu, G.; Lu, X. Regiocontrolled Coupling of Aromatic and Vinylic Amides with α-Allenols To Form γ-Lactams via Rhodium(III)-Catalyzed C-H Activation. *Org. Lett.* **2016**, *18*, 5668−5671. (g) Xuan, J.; Daniliuc, C. G.; Studer, A. Construction of Polycyclic γ-Lactams and Related Heterocycles via Electron Catalysis. *Org. Lett.* **2016**, *18*, 6372−6375.

(4) For recent reviews on C-H amidation, see: (a) Kim, H.; Chang, S. The Use of Ammonia as an Ultimate Amino Source in the Transition Metal-Catalyzed C-H Amination. *Acc. Chem. Res.* **2017**, *50*, 482−486. (b) Park, Y.; Kim, Y.; Chang, S. Transition Metal-Catalyzed C-H Amination: Scope, Mechanism, and Applications. *Chem. Rev.* **2017**, *117*, 9247−9301. (c) Jeffrey, J. L.; Sarpong, R. Intramolecular C(sp^3)-H amination. *Chem. Sci.* **2013**, *4*, 4092−4106. (d) Dequirez, G.; Pons, V.; Dauban, P. Nitrene Chemistry in Organic Synthesis: Still in Its Infancy? *Angew. Chem., Int. Ed.* **2012**, *51*, 7384−7395. (e) Collet, F.; Lescot, C.; Dauban, P. Catalytic C-H amination: the stereoselectivity issue. *Chem. Soc. Rev.* **2011**, *40*, 1926−1936. (f) Zalatan, D. N.; Du Bois, J. Metal-Catalyzed Oxidations of C-H to C-N Bonds. *Top. Curr. Chem.* **2009**, *292*, 347−378. (g) Davies, H. M. L.; Manning, J. R. Catalytic C-H functionalization by metal carbenoid and nitrenoid insertion. *Nature* **2008**, *451*, 417−424.

(5) (a) Svastits, E. W.; Dawson, J. H.; Breslow, R.; Gellman, S. H. Functionalized Nitrogen Atom Transfer Catalyzed by Cytochrome P-450. *J. Am. Chem. Soc.* **1985**, *107*, 6427−6428. (b) Breslow, R.; Gellman, S. H. Intramolecular Nitrene C-H Insertions Mediated by Transition-Metal Complexes as Nitrogen Analogues of Cytochrome P-450 Reactions. *J. Am. Chem. Soc.* **1983**, *105*, 6728−6729. (c) Breslow, R.; Gellman, S. H. Tosylamidation of Cyclohexane by a Cytochrome P-450 Model. *J. Chem. Soc., Chem. Commun.* **1982**, 1400−1401.

(6) (a) Ochiai, M.; Miyamoto, K.; Kaneaki, T.; Hayashi, S.; Nakanishi, W. Highly Regioselective Amination of Unactivated Alkanes by Hypervalent Sulfonylimino-λ^3-Bromane. *Science* **2011**, *332*, 448−451. (b) Michaudel, Q.; Thevenet, D.; Baran, P. S. Intermolecular Ritter-Type C-H Amination of Unactivated sp^3 Carbons. *J. Am. Chem. Soc.* **2012**, *134*, 2547−2550. (c) Sharma, A.; Hartwig, J. F. Metal-catalysed azidation of tertiary C-H bonds suitable for late-stage functionalization. *Nature* **2015**, *517*, 600−604. (d) Huang, X.; Bergsten, T. M.; Groves, J. T. Manganese-Catalyzed Late-Stage Aliphatic C-H Azidation. *J. Am. Chem. Soc.* **2015**, *137*, 5300−5303. (e) Hennessy, E. T.; Liu, R. Y.; Iovan, D. A.; Duncan, R. A.; Betley, T. A. Iron-mediated intermolecular N-group transfer chemistry with olefinic substrates. *Chem. Sci.* **2014**, *5*, 1526−1532. (f) Nishioka, Y.; Uchida, T.; Katsuki, T. Enantio- and Regioselective Intermolecular Benzylic and Allylic C-H Bond Amination. *Angew. Chem., Int. Ed.* **2013**, *52*, 1739−1742.

(7) (a) Hong, S. Y.; Park, Y.; Hwang, Y.; Kim, Y. B.; Baik, M.-H.; Chang, S. Selective formation of γ-lactams via C-H amidation enabled by tailored iridium catalysts. *Science* **2018**, *359*, 1016−1021. (b) Jung, H.-Y.; Chang, S.; Hong, S. Strategic Approach to the Metamorphosis of γ-Lactones to NH γ-Lactams via Reductive Cleavage and C-H Amidation. *Org. Lett.* **2019**, *21*, 7099−7103.

(8) (a) Wang, X.; Song, S.; Jiao, N. Rh-catalyzed Transient Directing Group Promoted C-H Amidation of Benzaldehydes Utilizing Dioxazolones. *Chin. J. Chem.* **2018**, *36*, 213−216. (b) Hermann, G. N.; Bolm, C. Mechanochemical Rhodium(III)-Catalyzed C-H Bond Amidation of Arenes with Dioxazolones under Solventless Conditions in a Ball Mill. *ACS Catal.* **2017**, *7*, 4592−4596. (c) Jeon, M.; Mishra, N. K.; De, U.; Sharma, S.; Oh, Y.; Choi, M.; Jo, H.; Sachan, R.; Kim, H. S.; Kim, I. S. Rh(III)-Catalyzed C-H Functionalization of Indolines

with Readily Accessible Amidating Reagent: Synthesis and Anticancer Evaluation. *J. Org. Chem.* **2016**, *81*, 9878−9885. (d) Mei, R.; Loup, J.; Ackermann, L. Oxazolinyl-Assisted C-H Amidation by Cobalt(III) Catalysis. *ACS Catal.* **2016**, *6*, 793−797. (e) Wang, F.; Wang, H.; Wang, Q.; Yu, S.; Li, X. Co(III)-Catalyzed Synthesis of Quinazolines via C-H Activation of N-Sulfinylimines and Benzimidates. *Org. Lett.* **2016**, *18*, 1306−1309. (f) Wang, F.; Jin, L.; Kong, L.; Li, X. Cobalt(III)- and Rhodium(III)-Catalyzed C-H Amidation and Synthesis of 4-Quinolones: C-H Activation Assisted by Weakly Coordinating and Functionalizable Enaminone. *Org. Lett.* **2017**, *19*, 1812−1815.

(9) (a) Park, Y.; Chang, S. Asymmetric formation of γ-lactams via C−H amidation enabled by chiral hydrogen-bond-donor catalysts. *Nat. Catal.* **2019**, *2*, 219−227. (b) Xing, Q.; Chan, C.-M.; Yeung, Y.-W.; Yu, W.-Y. Ruthenium(II)-Catalyzed Enantioselective γ-Lactams Formation by Intramolecular C-H Amidation of 1,4,2-Dioxazol-5-ones. *J. Am. Chem. Soc.* **2019**, *141*, 3849−3853. (c) Wang, H.; Park, Y.; Bai, Z.; Chang, S.; He, G.; Chen, G. Iridium-Catalyzed Enantioselective C(sp^3)-H Amidation Controlled by Attractive Noncovalent Interactions. *J. Am. Chem. Soc.* **2019**, *141*, 7194−7201. (d) Zhou, Z.; Chen, S.; Hong, Y.; Winterling, E.; Tan, Y.; Hemming, M.; Harms, K.; Houk, K. N.; Meggers, E. Non-C_2-Symmetric Chiral-at-Ruthenium Catalyst for Highly Efficient Enantioselective Intramolecular C(sp^3)-H Amidation. *J. Am. Chem. Soc.* **2019**, *141*, 19048−19057.

(10) Hwang, Y.; Park, Y.; Kim, Y. B.; Kim, D.; Chang, S. Revisiting Arene C(sp^2)-H Amidation by Intramolecular Transfer of Iridium Nitrenoids: Evidence for a Spirocyclization Pathway. *Angew. Chem., Int. Ed.* **2018**, *57*, 13565−13569.

(11) (a) Liu, J.-T.; Yang, S.; Tang, W.; Yang, Z.; Xu, J. Iridium-catalyzed efficient reduction of ketones in water with formic acid as a hydride donor at low catalyst loading. *Green Chem.* **2018**, *20*, 2118−2124. (b) Yang, S.; Tang, W.; Yang, Z.; Xu, J. Iridium-Catalyzed Highly Efficient and Site-Selective Deoxygenation of Alcohols. *ACS Catal.* **2018**, *8*, 9320−9326. (c) Yang, Z.; Luo, R.; Zhu, Z.; Yang, X.; Tang, W. Harnessing the Reactivity of Iridium Hydrides by Air: Iridium-Catalyzed Oxidation of Aldehydes to Acids in Water. *Organometallics* **2017**, *36*, 4095−4098. (d) Yang, Z.; Zhu, Z.; Luo, R.; Qiu, X.; Liu, J.-T.; Yang, J.-K.; Tang, W. Iridium-catalyzed highly efficient chemoselective reduction of aldehydes in water using formic acid as the hydrogen source. *Green Chem.* **2017**, *19*, 3296−3301. (e) Luo, N.; Liao, J.; Ouyang, L.; Wen, H.; Liu, J.; Tang, W.; Luo, R. Highly pH-Dependent Chemoselective Transfer Hydrogenation of α,β-Unsaturated Aldehydes in Water. *Organometallics* **2019**, *38*, 3025−3031.

(12) Geffken, D. 3(1-hydroxyalkyl)-1.4,2-dioxazole-5-one and 3-hydroxyoxazodine-2,4-dione from 2-hydroxycarbohydroxam acids and 1,1-carbonyldiimidazole. *Liebigs Ann. Chem.* **1982**, *1982*, 211−218.

(13) Xia, C.; White, A. J. P.; Hii, K. K. M. Synthesis of Isoindolinones by Pd-Catalyzed Coupling between N-Methoxybenzamide and Styrene Derivatives. *J. Org. Chem.* **2016**, *81*, 7931−7938.

(14) Wang, S.; Shao, P.; Du, G.; Xi, C. MeOTf- and TBD-Mediated Carbonylation of ortho-Arylanilines with CO_2 Leading to Phenanthridinones. *J. Org. Chem.* **2016**, *81*, 6672−6676.

https://dx.doi.org/10.1021/acs.joc.0c00157
J. Org. Chem. 2020, 85, 4430−4440